| Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer F Concha-Benavente, RM Srivastava, S Trivedi, Y Lei, U Chandran, ... Cancer research 76 (5), 1031-1043, 2016 | 335 | 2016 |
| Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer LM Kelly, G Barila, P Liu, VN Evdokimova, S Trivedi, F Panebianco, ... Proceedings of the National Academy of Sciences 111 (11), 4233-4238, 2014 | 297 | 2014 |
| Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study NJ Bahlis, MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, ... Leukemia 34 (7), 1875-1884, 2020 | 250 | 2020 |
| PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment J Li, HB Jie, Y Lei, N Gildener-Leapman, S Trivedi, T Green, LP Kane, ... Cancer research 75 (3), 508-518, 2015 | 242 | 2015 |
| Phase I dendritic cell p53 peptide vaccine for head and neck cancer PJ Schuler, M Harasymczuk, C Visus, A DeLeo, S Trivedi, Y Lei, A Argiris, ... Clinical Cancer Research 20 (9), 2433-2444, 2014 | 175 | 2014 |
| Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients S Trivedi, RM Srivastava, F Concha-Benavente, S Ferrone, ... Clinical Cancer Research 22 (21), 5229-5237, 2016 | 159 | 2016 |
| CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer RM Srivastava, S Trivedi, F Concha-Benavente, SP Gibson, C Reeder, ... Clinical Cancer Research 23 (3), 707-716, 2017 | 126 | 2017 |
| Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma KD McCormick, A Ghosh, S Trivedi, L Wang, CB Coyne, RL Ferris, ... Carcinogenesis 37 (5), 522-529, 2016 | 88 | 2016 |
| Human papillomavirus 16 E 6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence KA Lang Kuhs, AR Kreimer, S Trivedi, D Holzinger, M Pawlita, RM Pfeiffer, ... Cancer 123 (22), 4382-4390, 2017 | 77 | 2017 |
| STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients RM Srivastava, S Trivedi, F Concha-Benavente, J Hyun-Bae, L Wang, ... Cancer immunology research 3 (8), 936-945, 2015 | 74 | 2015 |
| THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer F Panebianco, LM Kelly, P Liu, S Zhong, S Dacic, X Wang, AD Singhi, ... Proceedings of the National Academy of Sciences 114 (9), 2307-2312, 2017 | 71 | 2017 |
| EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1–TUFM protein complex Y Lei, BA Kansy, J Li, L Cong, Y Liu, S Trivedi, H Wen, JPY Ting, ... Oncogene 35 (36), 4698-4707, 2016 | 68 | 2016 |
| Immune biomarkers of anti-EGFR monoclonal antibody therapy S Trivedi, F Concha-Benavente, RM Srivastava, HB Jie, SP Gibson, ... Annals of Oncology 26 (1), 40-47, 2015 | 51 | 2015 |
| Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or … JL Kaufman, SZ Usmani, J San-Miguel, N Bahlis, DJ White, L Benboubker, ... Blood 134, 1866, 2019 | 48 | 2019 |
| Comparative outcomes of severe obstructive sleep apnea in pediatric patients with Trisomy 21 PJ Thottam, S Trivedi, B Siegel, K Williams, D Mehta International journal of pediatric otorhinolaryngology 79 (7), 1013-1016, 2015 | 45 | 2015 |
| Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells Y Gao, S Trivedi, RL Ferris, K Koide Scientific reports 4 (1), 6098, 2014 | 45 | 2014 |
| Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety … MA Dimopoulos, DJ White, L Benboubker, G Cook, M Leiba, J Morton, ... Blood 130, 739, 2017 | 44 | 2017 |
| Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM … KC Weisel, P Sonneveld, MV Mateos, VTM Hungria, A Spencer, J Estell, ... Blood 134, 3192, 2019 | 40 | 2019 |
| Characterization of human papillomavirus antibodies in individuals with head and neck cancer KAL Kuhs, M Pawlita, SP Gibson, NC Schmitt, S Trivedi, A Argiris, ... Cancer epidemiology 42, 46-52, 2016 | 37 | 2016 |
| Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer RL Ferris, JL Geiger, S Trivedi, NC Schmitt, DE Heron, JT Johnson, S Kim, ... Annals of Oncology 27 (12), 2257-2262, 2016 | 36 | 2016 |
